OPEN X Health’s Post

𝗔𝗻𝗲𝗿𝘃𝗲𝗮: 𝗥𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗶𝘇𝗶𝗻𝗴 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝘄𝗶𝘁𝗵 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀 In the ever-evolving landscape of healthcare, true innovation lies in strategic services that reshape how we approach pharmaceuticals and patient care. Anervea stands out as a trailblazer in this realm, offering specialized services that are transforming the industry. 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗜𝗻𝘀𝗶𝗴𝗵𝘁 𝘄𝗶𝘁𝗵 𝗔𝗻𝗲𝗿𝘃𝗲𝗮'𝘀 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀 Anervea's comprehensive suite of services is designed to offer deep market insights and a nuanced understanding of the pharmaceutical sector. These services are not just about gathering data; they're about interpreting it in a way that empowers healthcare professionals and companies to make informed, strategic decisions. 𝗣𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻: 𝗔𝗻𝗲𝗿𝘃𝗲𝗮’𝘀 𝗖𝗼𝗺𝗺𝗶𝘁𝗺𝗲𝗻𝘁 𝘁𝗼 𝗣𝗮𝘁𝗶𝗲𝗻𝘁-𝗖𝗲𝗻𝘁𝗿𝗶𝗰 𝗖𝗮𝗿𝗲 At the heart of Anervea's mission is the personalization of healthcare. Their services ensure that strategies and solutions are tailored to meet the unique needs of patients, echoing the belief that effective care is individualized care. 𝗗𝗿𝗶𝘃𝗶𝗻𝗴 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗘𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆 𝗮𝗻𝗱 𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗶𝘃𝗲𝗻𝗲𝘀𝘀 Anervea's vision encompasses a more efficient, agile healthcare industry. By providing services that leverage real-time analytics and predictive insights, they are not just responding to market needs but anticipating them, setting new standards in healthcare operations. 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝘃𝗲 𝗣𝗿𝗼𝗴𝗿𝗲𝘀𝘀 𝗶𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 Anervea champions a collaborative approach, uniting different sectors of the healthcare industry to forge innovative, patient-focused solutions. Their services are catalysts, sparking significant advancements in healthcare. Y𝗼𝘂𝗿 𝗣𝗲𝗿𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲 𝗠𝗮𝘁𝘁𝗲𝗿𝘀 As we witness this transformative era in healthcare, your perspective is invaluable. How do you see Anervea's services shaping the future of the industry? What impact do you envision for patient care and pharmaceutical strategies? #Anervea #HealthcareInnovation #PatientCare #PharmaceuticalIndustry #HealthcareServices #FutureOfHealthcare #PersonalizedMedicine #HealthcareStrategy #IndustryEfficiency #DigitalHealthcare

Having celebrated World Pharmacist Day, with this year’s theme, Pharmacists: Meeting Global Health Needs, I feel the need to touch on the competition within the pharmaceutical industry. For us pharmacists to truly give ourselves the opportunity to meet the rapidly growing healthcare needs of people around the world, we need to think more collaboration and less competition. Forming strategic partnerships with complementary companies, both within and outside of healthcare, can unlock new resources, markets, and technologies. By working together, we can leverage our collective strengths to drive mutual growth. One promising approach, given the rapid expansion of technology’s influence on people’s lives, is co-developing solutions with tech startups that offer services that support our mission. This collaboration can help build a more holistic and robust platform to extend our patient-centered care services to more people. We can still bring original, creative ideas to the table within strategic partnerships, ideas that will definitely be credited to us. Owning the latest tech products alone won’t guarantee the global impact we need, but collaboration can lead to greater innovative solutions and expanded market reach. #worldpharmacistday’24 #pharmacistscare #globalhealth #healthcareheroes #pharmacylife #patientcare #healthinnovation #pharmacistsinaction #collaborationinhealth #healthtech

In the world of health and pharma, digital products hold immense potential for enhancing engagement, improving customer experience, and driving business growth. However, there is a chronic pattern within organisations in the sector — a tendency to create, launch, and subsequently neglect these digital products. Our CEO, Rob Verheul, writes here for the latest edition of Pharma Times Magazine about the challenge of sustaining digital products in pharma organisations, and what can be done to overcome it. #lifeafterlaunch #digitalpharma #customerexperience PharmaTimes Media Ltd

Market access and pricing strategies to drive out the competition? If you think, the price is decided based on the manufacturing, marketing, packaging and distribution costs keeping certain percentage as profit, you are wrong. Read below to understand: Pharmaceutical and biotech companies bring their products to market to ensure long-term sustainability and profitability. Here are some key considerations and strategies in these areas: - Value Proposition: Clearly articulate the value proposition of their products, demonstrating how they address unmet medical needs, improve patient outcomes, or provide cost savings to healthcare systems. - Health Economic Evidence: Generating robust health economic evidence through cost-effectiveness analyses, budget impact studies, and real-world evidence can strengthen the value proposition and support pricing negotiations with payers. - Pricing Strategy: Companies must carefully consider their pricing strategy, taking into account factors such as therapeutic class competition, clinical differentiation, and willingness-to-pay thresholds in target markets. - Access Negotiations: Engaging in proactive and collaborative negotiations with payers, including government agencies, insurers, and pharmacy benefit managers, is crucial to secure favorable reimbursement terms and formulary placement for products. - Risk-sharing Agreements: Implementing risk-sharing agreements with payers, such as outcome-based pricing or pay-for-performance models, can align incentives, mitigate payer risk, and facilitate market access by linking product reimbursement to real-world outcomes. - Patient Assistance Programs: Offering copay assistance, patient access schemes, or compassionate use programs, can help address affordability barriers and improve patient access to essential therapies. - Early Engagement with Payers: Discussions with payers early in the product development lifecycle to understand their requirements, gather insights into pricing and reimbursement expectations. - Formulary Strategies: Developing tailored formulary strategies, including tiered formulary placement, preferred status agreements, and value-based contracting, can enhance product access and uptake within managed care organizations and health systems. - Global Pricing and Access Considerations: Recognizing the diversity of healthcare systems and payer dynamics across different countries and regions. Customized pricing and access strategies tailored to local market conditions, regulatory requirements, and healthcare priorities. Overall, successful market access and pricing strategies require a multifaceted approach that integrates clinical, economic, and stakeholder perspectives to deliver value to patients, healthcare providers and payers while ensuring sustainable commercial success for pharmaceutical and biotech products. Next post -Payer-provider dynamics! #marketaccess #pricingstrategy #CEO #pharma #biotech #marketentry #competitiveanalysis

💡 Did you know the future of pharmacy is rooted in digital transformation? On this World Pharmacist Day, we’re recognising the vital role pharmacists play in safeguarding patient health across the globe. At Revolve Healthcare, we believe that the future of pharmacy goes far beyond traditional practices. With advancements in personalised medicine and digital health solutions, the pharmaceutical industry is undergoing a rapid transformation. PharmaTech innovations - such as enhanced drug tracking, patient data management, and medication adherence tools - are reshaping the way care is delivered. 💻 We’re proud to be part of this digital shift, developing innovative digital pharma solutions that empower pharmacists to provide more tailored and effective care. By blending technology with the expertise of healthcare professionals, we’re helping to create a more connected and efficient healthcare system. Let’s embrace this transformation together and build a future where pharmacists are supported by advanced tools, enabling them to focus on what they do best—caring for patients. #WorldPharmacistDay #PharmaTech #DigitalHealth #DigitalTransformation

There’s been lots of announcements recently about new medicines and new technologies being reimbursed (including today’s news: ‘Six additions to the PBS” - Pharma in Focus). This is prompting conversations around ‘Launch Excellence’ and what’s required for success.    Planning for success starts early…from the very first conversation with the KOLs; by understanding the treatment pathways and the patient perspective; by building the initial frameworks for cross-functional collaboration…and more.    The attached article highlights how Medical Affairs is driving these early stages and is a key partner throughout the entire process.   All the best, Glenn Glenn Carter Healthcare Professionals Group #MedicalAffairs #LaunchExcellence

🔎Patient centricity- words or action? An insightful session yesterday hosted by the BHBIA on the importance of patient centricity and whether it always exists. Thank you to all speakers- Merope Mills (The Guardian, Martha’s rule) Emma Sutcliffe (ISEP), Partha S Kar (NHS), Shannon Altimari (GSK), Mark Bradley (PeopleWith) 🎆Key Takeaways:   💪 The power of patient organisations: Patient orgs are now reshaping regulatory discussions previously dominated by pharmaceuticals. Involving patients in clinical trial design not only results in better medicines but also empowers patients, improves treatment adherence and identifies unmet needs.   👥The importance of the patient/physician relationship: “The single biggest problem in communication is the illusion that it has taken place”. Language matters- never underestimate the impact words have- while clinicians may feel they have had a good consultation, often only 20% of patients feel the same. 🤝Pharmaceutical companies and patient centricity: An internal culture shift can be required to embrace a patient- centric approach, but understanding patients through patient journeys, experience and community partnerships can drive significant impact. #patientengagement #patientcentricity

How Digital Health Creates Value for Pharmaceutical Companies Across the Asset & Patient Journey 💡This great report from IQVIA examines the business case and value of digital health for pharmaceutical companies. 🚀Key Takeaways: 👉1 Digital health solutions can enhance asset value across product discovery, development, clinical/regulatory strategies and commercialization. 👉2 Pharma is focusing digital health investments on: establishing standalone revenue streams, improving asset performance, de-risking development, and omnichannel engagement. 👉3 Organizational models like joint ventures, embedded digital groups, orchestrators and accelerators/incubators help pharma innovate in digital health. 👉4 Partnerships with digital health companies are a strategic necessity to enhance capabilities, diversify offerings and reach broader audiences. 👉5 Various partnership models enable digital health innovation, from licensing deals to development collaborations and joint ventures. 📈With nearly 79% YoY growth in disease-specific apps, digital health is transforming healthcare and pharma is at the forefront leveraging these technologies. Authors: Nick Mageras Brian Lovinguth #DigitalHealth #Pharma #Healthcare #PatientJourney

Here are a few questions pharmaceutical and medical device companies can ask to distinguish high-quality companies from those that might not be around in a year. Forbes shares a great read on How Pharma Can Borrow A Page From Digital Health Investors’ Playbook BeeSeen Solutions is a Full-Service Strategic Advisory, with over 25 years of experience. We provide access to a Global Footprint of Professionals, a Full Suite of Digital Strategies and Next Generation Technologies clients across diverse industries can benefit from. Source: https://bit.ly/3HI933Z More Information, Get In Touch Today: info@beeseensolutions.com (631) 777-8811 BeeSeen Solutions BeeSeen Legal #Beeseensolutions #Motivation #strageticadvisory #Strageticstaffing,#Digitalmarketing #SEO #UIUX #BPO #Outsourcing

🌟 Why Life Science Comapnies use Real World Evidence?🌟 Real-world Evidence 📜is transforming the way we understand patient experiences and outcomes, guiding healthcare decisions for the better. As we delve into patient lifetimes and personal journeys, we gain valuable insights that inform the medical community and decision-makers on what truly works for individuals. 🟢Payers are increasingly recognizing the importance of providing access to innovative drugs, even with high upfront costs, when long-term savings and patient benefits are evident. This shift towards prioritizing patient outcomes is a game-changer in healthcare. 🟢Moreover, by improving the quality of risk-sharing agreements between pharmaceutical companies and payers, we can ensure that access to cutting-edge solutions remains uninterrupted. These agreements, based on real-world outcomes, pave the way for sustainable collaborations that benefit all parties involved. 🟢Also that will support Pharma companies to improve the clinical & economic value of their drugs & medical devices, accelerate the process of regulatory approval & reduce financial burdens, amenable higher quality of care & improve patient’s outcumes . 💊 #HealthcareInnovation #RealWorldData #PatientOutcomes #CollaborationGoals